2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning. Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are two cash-producing companies that reinvest wisely to drive long-term success and one that may face some trouble. Trailing 12-Month Free Cash Flow Margin: 10.4% With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine. Why Do We Pass on SUPN? Sales trends were unexciting over the last five years as its 5.9% annual growth was below the typical healthcare company Modest revenue base of $681.5 million gives it less fixed cost leverage and fewer distribution channels than larger companies Waning returns on capital from an already weak starting point
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Lupin Launches Topiramate Extended-Release Capsules in the United States [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SUPN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WalMarketBeat
- Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- 3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]Yahoo! Finance
SUPN
Earnings
- 11/4/25 - Miss
SUPN
Analyst Actions
- 12/19/25 - Stifel
SUPN
Sec Filings
- 2/2/26 - Form SCHEDULE
- 1/28/26 - Form 8-K
- 1/21/26 - Form SCHEDULE
- SUPN's page on the SEC website